Healthcare provider profile · identity verified

Smita Murty, MD

Internal Medicine · CHAMPAIGN, IL · NPI 1447493945

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	424	117
Amlodipine Besylate	Amlodipine Besylate	318	99
Levothyroxine Sodium	Levothyroxine Sodium	251	66
Lisinopril	Lisinopril	232	68
Gabapentin	Gabapentin	227	49
Losartan Potassium	Losartan Potassium	207	64
Carvedilol	Carvedilol	197	44
Pantoprazole Sodium	Pantoprazole Sodium	175	47
Furosemide	Furosemide	158	45
Hydralazine Hcl	Hydralazine Hcl	158	46
Metoprolol Succinate	Metoprolol Succinate	144	33
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	136	22
Rosuvastatin Calcium	Rosuvastatin Calcium	112	32
Allopurinol	Allopurinol	95	27
Jardiance	Empagliflozin	90	16
Albuterol Sulfate Hfa	Albuterol Sulfate	88	31
Potassium Chloride	Potassium Chloride	87	28
Omeprazole	Omeprazole	86	33
Trazodone Hcl	Trazodone Hcl	86	23
Metformin Hcl Er	Metformin Hcl	84	22
Tizanidine Hcl	Tizanidine Hcl	80	19
Metformin Hcl	Metformin Hcl	71	19
Buspirone Hcl	Buspirone Hcl	69	18
Hydrochlorothiazide	Hydrochlorothiazide	69	25
Sevelamer Carbonate	Sevelamer Carbonate	66	21
Simvastatin	Simvastatin	65	17
Eliquis	Apixaban	63	16
Alendronate Sodium	Alendronate Sodium	62	15
Alprazolam	Alprazolam	62	13
Famotidine	Famotidine	60	suppressed
Spironolactone	Spironolactone	60	17
Sertraline Hcl	Sertraline Hcl	58	18
Montelukast Sodium	Montelukast Sodium	56	13
Veltassa	Patiromer Calcium Sorbitex	52	14
Pravastatin Sodium	Pravastatin Sodium	51	13
Fluoxetine Hcl	Fluoxetine Hcl	50	suppressed
Clopidogrel	Clopidogrel Bisulfate	49	16
Ozempic	Semaglutide	49	11
Citalopram Hbr	Citalopram Hydrobromide	48	13
Farxiga	Dapagliflozin Propanediol	45	suppressed
Tramadol Hcl	Tramadol Hcl	45	15
Calcitriol	Calcitriol	44	14
Torsemide	Torsemide	43	16
Venlafaxine Hcl Er	Venlafaxine Hcl	43	13
Xarelto	Rivaroxaban	42	suppressed
Bupropion Xl	Bupropion Hcl	40	14
Paroxetine Hcl	Paroxetine Hcl	40	suppressed
Clonidine Hcl	Clonidine Hcl	39	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	11
Mirtazapine	Mirtazapine	37	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	37	12
Donepezil Hcl	Donepezil Hcl	35	suppressed
Ropinirole Hcl	Ropinirole Hcl	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	34	12
Metoprolol Tartrate	Metoprolol Tartrate	34	12
Duloxetine Hcl	Duloxetine Hcl	33	suppressed
Ezetimibe	Ezetimibe	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	31	12
Lorazepam	Lorazepam	30	12
Pregabalin	Pregabalin	30	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	30	13
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Calcium Acetate	Calcium Acetate	29	suppressed
Kerendia	Finerenone	29	suppressed
Atenolol	Atenolol	27	suppressed
Midodrine Hcl	Midodrine Hcl	27	suppressed
Naproxen	Naproxen	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	22
Glipizide	Glipizide	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Glipizide Er	Glipizide	24	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Velphoro	Sucroferric Oxyhydroxide	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Ondansetron Odt	Ondansetron	21	11
Chlorthalidone	Chlorthalidone	20	suppressed
Varenicline Tartrate	Varenicline Tartrate	19	suppressed
Incruse Ellipta	Umeclidinium Bromide	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Metolazone	Metolazone	18	suppressed
Ramelteon	Ramelteon	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Azithromycin	Azithromycin	17	17
Baclofen	Baclofen	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Ketoconazole	Ketoconazole	16	12
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Topiramate	Topiramate	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Repatha Sureclick	Evolocumab	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Cephalexin	Cephalexin	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Celecoxib	Celecoxib	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Sevelamer Hcl	Sevelamer Hcl	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error